Table 4.
Preclinical representation of several H3R antagonists in different animal models of SCH.
| Ligand | Dose (mg/kg) | Species | Pharmacological effect observed | References |
|---|---|---|---|---|
| Thioperamide | 10 and 30 (i.p.) | Mice | Increase of prepulse inhibition | Browman et al., 2004; Sadek et al., 2016 |
| Ciproxifan | 1, 3, and 10 (i.p.) | Mice | Increase of prepulse inhibition | Browman et al., 2004; Sadek et al., 2016 |
| ABT-239 | 0.3-3.0 (i.p.) | Rats | Decrease of cognitive deficits induced by ketamine and MK-801 | Brown et al., 2013; Sadek et al., 2016 |
| A-431404 | 0.3-3.0 (i.p.) | Mice | Decrease of cognitive deficits induced by ketamine and MK-801 | Browman et al., 2004; Sadek et al., 2016 |
| SAR110894 | 0.3-3 (p.o.) | Mice | Decrease in Impaired social behaviors | Griebel et al., 2012; Sadek et al., 2016 |
| 0.3-1 (p.o.) | Rats | Decrease in Impaired social behaviors | Griebel et al., 2012; Sadek et al., 2016 |